金宇生物技术股份有限公司发布股份回购预案，回购规模最高达4亿元
要点摘要
- 回购金额：不低于2亿元（含），不超过4亿元（含）
- 回购价格上限：20.74元/股（不高于决议前30个交易日均价的150%）
- 回购股份数量：预计约964.32万股至1928.64万股，占总股本0.87%~1.73%
- 回购方式：通过上交所集中竞价交易方式
- 回购期限：董事会通过后3个月内
- 资金来源：公司自有资金或自筹资金
- 回购用途：维护公司价值及股东权益
- 董事、高管及大股东未来3-6个月无减持计划
- 回购后股份如12个月后出售不完，3年内未售完部分将注销
详细解读
回购方案背景及动因
金宇生物技术股份有限公司（证券代码：600201）董事会于2026年6月5日审议通过了股份回购预案。此次回购主要目的是在公司股价近期大幅下跌、累计跌幅超过20%的背景下，维护公司价值、增强投资者信心，保护全体股东利益。公司董事长张翀宇于2026年6月3日提出本次回购建议，董事会全票通过，无需提交股东大会审议。
回购具体安排
- 回购资金总额不低于2亿元、不超过4亿元，资金来源为自有或自筹。
- 回购股份价格不高于20.74元/股，具体价格由管理层根据市场情况在回购期内择机确定。
- 按上限测算，预计回购约1928.64万股，占公司总股本约1.73%；按下限测算，约964.32万股，占0.87%。
- 回购期限为董事会审议通过后3个月内，若因重大事项股票停牌10日以上，回购期顺延。
- 回购股份通过上交所集中竞价交易方式实施。
- 回购股份拟用于维护公司价值及股东权益，而非注销、员工持股计划或可转债转换。
资金与财务影响
截至2026年3月31日，公司总资产约65.37亿元，净资产约54.61亿元，流动资产约23.75亿元。即使最高回购金额4亿元，也分别占总资产、净资产及流动资产的6.12%、7.32%、16.84%，对公司日常经营、财务、盈利能力、债务履行和未来发展影响有限。公司自有资金充足，不会损害债权人利益。
股权结构影响
回购完成后，股份全部为无限售条件流通股，持股结构未发生本质变化，公司上市地位不受影响，亦不会导致控股权变更。
大股东及高管承诺
- 公司董事、高管、持股5%以上股东内蒙古金宇生物控股有限公司及其一致行动人在未来3个月、6个月内不存在减持计划。
- 公司第一大股东“生物控股”正在实施5000万至1亿元的增持计划，与本次回购无利益冲突，也未发生内幕交易及市场操纵。
- 如后续拟减持，将严格履行信息披露义务。
回购股份的后续安排
回购股份将在披露回购结果公告12个月后通过集中竞价方式出售，若3年内未售完，将依法注销。回购期间如遇重大事项或市场、监管政策变化，董事会有权调整或终止回购方案。
风险提示
- 若公司股价持续高于回购上限价格，回购计划可能无法顺利实施。
- 如遇重大事项、公司经营财务状况或外部环境变化，也可能导致回购方案变更或终止。
- 政策调整可能影响回购条款的执行。
- 投资者需关注公司后续公告，注意相关投资风险。
对投资者的潜在影响与价格敏感点
- 本次大规模回购显示公司对自身价值有高度信心，或有助于稳定股价，提升市场信心，短期内对股价构成正面刺激。
- 大股东持续增持且未来半年无减持计划，进一步强化市场对公司未来的信心。
- 回购股份未来将择机出售，如3年内未售完则注销，可能带来股份减少、每股收益提升的预期。
- 若公司股价反弹超越回购上限，则回购实施难度增加，投资者需关注股价动态。
结语
此次回购方案不仅规模大、实施严格、且对投资者利益保护充分，显示管理层对公司长远发展的信心。投资者应密切关注公司后续公告及回购进展，合理评估预案对股价的影响与潜在机会。
免责声明：本文信息来源于公司公告，仅供参考，不构成投资建议。股市有风险，投资需谨慎。投资者应结合自身情况做出独立判断。
English Version
Jinyu Bio-Technology Announces Share Buyback Plan up to 400 Million RMB
Key Highlights
- Buyback Amount: No less than RMB 200 million, up to RMB 400 million
- Buyback Price Cap: RMB 20.74/share (not exceeding 150% of 30-day average)
- Buyback Volume: Estimated 9.64–19.29 million shares, 0.87%–1.73% of total shares
- Buyback Method: Centralized bidding via Shanghai Stock Exchange
- Buyback Period: Within 3 months from board approval
- Source of Funds: Internal or self-raised funds
- Use of Buyback Shares: For maintaining company value and shareholder interests
- No reduction plans by directors, executives, or major shareholders in next 3-6 months
- Unsold shares within 3 years after 12 months post-buyback will be canceled
In-depth Analysis
Background and Purpose
Jinyu Bio-Technology (Stock Code: 600201) board approved a share buyback plan on June 5, 2026. The move comes after a cumulative 20%+ drop in share price over 20 consecutive trading days. The buyback aims to stabilize the company value, boost investor confidence, and protect shareholder interests. Initiated by Chairman Zhang Chongyu on June 3, 2026, the plan was unanimously approved by the board and does not require shareholder meeting approval.
Buyback Details
- Total buyback fund between RMB 200–400 million, funded by internal or self-raised funds.
- Share price cap set at RMB 20.74; actual buyback price to be determined by management according to market conditions.
- At the upper limit, up to 19.29 million shares (1.73% of total); at the lower limit, 9.64 million shares (0.87%).
- Buyback period is 3 months post board approval, with extension possible if trading is suspended for over 10 days due to major events.
- Shares will be bought on the open market through centralized bidding on the SSE.
- Purpose is to maintain company value and shareholder rights, not for capital reduction, employee incentives, or convertible bond conversion.
Financial Impact
As of March 31, 2026: Total assets about RMB 6.54 billion, net assets RMB 5.46 billion, current assets RMB 2.38 billion. Even at the maximum RMB 400 million buyback, the impact on total assets, net assets, and current assets would be 6.12%, 7.32%, and 16.84% respectively, judged to have limited impact on daily operations, financial status, profitability, debt repayment, and future development. Funding is sound and creditor rights will not be harmed.
Shareholding Structure Impact
After the buyback, all shares remain unrestricted and freely tradable, with no substantive change in structure or control. Listing status is unaffected.
Major Shareholder & Executive Commitments
- Directors, executives, and 5%+ shareholders (including Inner Mongolia Jinyu Bio-Control) and their concerted parties have no plan to reduce holdings in the next 3-6 months.
- Major shareholder Bio-Control is actively increasing its position (plan: RMB 50–100 million), with no conflict of interest or insider trading.
- Any future share reductions will be promptly disclosed per regulations.
Post-Buyback Handling
Shares repurchased will be sold via centralized bidding after 12 months post-buyback result announcement. Any shares not sold within 3 years will be canceled. The board reserves the right to adjust or terminate the plan should major events or market/regulatory changes occur.
Risks
- If the share price stays above the buyback cap, the plan may not proceed smoothly.
- Major events or changes in operations, finances, or external conditions could affect or end the plan.
- Policy updates may require amendments to the buyback terms.
- Investors should keep an eye on future company announcements and relevant risks.
Potential Impact & Price Sensitivity
- The scale and decisiveness of the buyback signals strong management confidence, likely to support and stabilize the share price in the short term.
- Major shareholders are increasing their holdings with no reduction plan, which is a positive signal for the company’s future.
- Repurchased shares not sold within 3 years will be canceled, which could reduce outstanding shares and improve per-share earnings.
- If the stock price rebounds above the buyback cap, execution may become difficult. Investors should monitor price movements closely.
Conclusion
This buyback plan is sizable, strictly implemented, and protective of investor interests, clearly reflecting management’s long-term confidence. Investors should follow further announcements and assess the plan’s actual impact and related opportunities.
Disclaimer: The information above is sourced from company announcements and is for reference only. It does not constitute investment advice. Stock market investments carry risks. Please make independent investment decisions based on your personal circumstances.
